FDA approves Ocaliva for rare, chronic liver disease - FDA.gov

CNA Finance

FDA approves Ocaliva for rare, chronic liver disease FDA.gov On Friday, May 27, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate ... Why Intercept Pharmaceuticals Inc (ICPT) is an Attractive Acquisition TargetBidness ETC Intercept Pharmaceuticals (ICPT) Stock: FDA Approves OcalivaCNA Finance (press release) 3 Reasons Goldman Sachs Still Neutral On Intercept PharmaBenzinga InvestorGuide -Monthly Prescribing Reference (registration) -Proactive Investors USA & Canada -Wall Street 24 all 13 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNE3aqFYCLuPAMxAvXjbBVmi1C2aog&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779124035805&ei=8bJNV9DTE8qe3QGrtp64Bg&url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503964.htm
via IFTTT